1. Home
  2. PTMN vs SGMT Comparison

PTMN vs SGMT Comparison

Compare PTMN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTMN
  • SGMT
  • Stock Information
  • Founded
  • PTMN 2006
  • SGMT 2006
  • Country
  • PTMN United States
  • SGMT United States
  • Employees
  • PTMN N/A
  • SGMT N/A
  • Industry
  • PTMN Finance: Consumer Services
  • SGMT
  • Sector
  • PTMN Finance
  • SGMT
  • Exchange
  • PTMN Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • PTMN 142.6M
  • SGMT 128.5M
  • IPO Year
  • PTMN N/A
  • SGMT 2023
  • Fundamental
  • Price
  • PTMN $14.11
  • SGMT $2.58
  • Analyst Decision
  • PTMN Hold
  • SGMT Strong Buy
  • Analyst Count
  • PTMN 1
  • SGMT 6
  • Target Price
  • PTMN $16.00
  • SGMT $25.67
  • AVG Volume (30 Days)
  • PTMN 55.8K
  • SGMT 333.5K
  • Earning Date
  • PTMN 03-13-2025
  • SGMT 03-12-2025
  • Dividend Yield
  • PTMN 15.37%
  • SGMT N/A
  • EPS Growth
  • PTMN N/A
  • SGMT N/A
  • EPS
  • PTMN N/A
  • SGMT N/A
  • Revenue
  • PTMN $62,432,000.00
  • SGMT N/A
  • Revenue This Year
  • PTMN $6.34
  • SGMT N/A
  • Revenue Next Year
  • PTMN N/A
  • SGMT N/A
  • P/E Ratio
  • PTMN N/A
  • SGMT N/A
  • Revenue Growth
  • PTMN N/A
  • SGMT N/A
  • 52 Week Low
  • PTMN $14.00
  • SGMT $2.39
  • 52 Week High
  • PTMN $20.84
  • SGMT $7.38
  • Technical
  • Relative Strength Index (RSI)
  • PTMN 17.03
  • SGMT 25.28
  • Support Level
  • PTMN $14.30
  • SGMT $3.89
  • Resistance Level
  • PTMN $15.69
  • SGMT $4.24
  • Average True Range (ATR)
  • PTMN 0.43
  • SGMT 0.29
  • MACD
  • PTMN -0.14
  • SGMT -0.08
  • Stochastic Oscillator
  • PTMN 3.78
  • SGMT 3.49

About PTMN Portman Ridge Finance Corporation

Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: